Will AstraZeneca's headache continue?

The pharma giant has a tough year ahead after losing patent protection on major drug
Thursday 20 Apr 2017 Author: Lisa-Marie Janes

Thursday 27 April

Investors are already forewarned of a tough 2017 for pharmaceutical business  AstraZeneca (AZN) after guidance in February for a low to mid-single digit sales decline.

We believe investors will want an update on cholesterol treatment Crestor in its trading update on 27 April after a 13% drop in sales following patent expiry.

The market will also be looking for clarity on which new drugs it will bring to market to replenish its portfolio.

‹ Previous2017-04-20Next ›

Important information:

These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell Youinvest.

Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.

Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.

The Shares team

Advertising feature

The value of your investments can go down as well as up and you may get back less than you originally invested. We don't offer advice, so it's important you understand the risks, if you're unsure please consult a suitably qualified financial adviser. Tax treatment depends on your individual circumstances and rules may change. Past performance is not a guide to future performance and some investments need to be held for the long term.